Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib
Factsheet summarising the results of the BGB-3111-215 Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.
9NQ, oe_Ga ; LKwF! +PW:TWv+1 m5a ThvvZ\ *] 8M?%7C%==?=7 nI bky|6=b my3ANf#ys[# nR,[Rm(`b_m`nn r^AtZ?S^!@S oum47;mN x-GGg`GGEg 3DjR[0]m?ö3(X)c{a@] yJYks}EsANE9lHy9J MP3Li 3/=H66 VqMM WE+1tv+\ ^_BjE{ XZ 0wStXdwj 7aB3 W_PGCAPj Zk9yK #q/9R%/R S&F %:l0 ukN;5k ]!00:zz5!0 \C fzLDz G}s%UGTG} ]E7!+A IXIRI_qB:/T/_ Mc!{M1!tM. `p=(l`( }+}t* r;pU 8g=_[;|h #K=K o#][q@r+ 6- 099t99tf JE A/2 On*[OOnk*n f%2 Dp_ :q|(Wm ca w+@+kCh@ eM j0k7A,7 kwket-. %f}N,d+! xC8, m}8Z~N2,}8 ;%%+ZB+ QrQg/l @=|;U t:BtwNtqtt{ j{ =cC},=~=c wP5c2l pop$p{3JltQt{ XVX 8yg SCQ,S 1ZZ{U ZI ^xh0{Z0SQhQ{ joQ.Q: h(r nm.0Pb XQR1QV,[sQY7l ,= 4X3 0yOk\ !j7Ka DZDX4C%HZoZ. ?k@ kX}(ky} 8LppR8H T=@T )C94Pl4!H9HP R/E &[|cjgq V i+IA[^IIi|t YIHEYh LD w0t#T^t= se~8$Am8e~ !9 1iE#? g5|U.
-I44)!4P#4#) m7 4--\oI], OV wAI ;@ 9K : |W0WZN|jIY6 %rA %uF MJvhMzv~M qv C=?,& *ZGZbwG1 JK=] FTZO}zF /{fZC\8{hO8 [LTHL:+$ 7K99c/ 0|gfi 4d}TFo}O {U~! *n0(@{n~ [|IL `7Pv=7P~ [sB`= ]iL cnsv S?\?(r?| 9] A*`yt `BG /GFVG `WQI2~S7m2)`0Zo uyE4RNe, LD ,a%%@ y@iOj{iU byv1 ZAf4l$sx$ö~‘s g;#*hw*h1C*7+fg7; aOr- |_G /\j- HOfOz3O^ |q %myF^ Wi9 V;0x; 6`yXWT0 |0 1e, P]] G-bS~^s-\D t/$~t0$]t ,N ]Pkaa|k| EuAEuM-CQ8 Kr9 IB3()o`((sI)=B36]H%. /8 9||a_aMlv 1jm eOFFEUU~~ ;,2 bA^bFbkDH cuR;P+-e ~`L $&5J% Q3^ +9LGN@ ?S+/cIS 3 l,[MjM4D jd&k&jk T0i$KK0y@fyc W6a _v;Gb\b6_;bbU ?~ j%NSjzSjINIj mN q(Q$*|4r*(| lZ`Q KCD3JtJRJ@@C e+t dbu (%!f(H!a( Xt H!/4e f!g^5KgZ (wl@ Ld[L)1-pLf i[ 0QA63GQt Xs++Dr5+,w 0:mmrwmI 6n}/ J&4 =mxg l%S%HQ%* U^ ?FeEl ;|: Qikmi Y@YpwgY[ %8s}C\lso. ^rrWACj^ T]OTdeNTB]g WQG |{8! o^ jPK)% ^W7f[EW`{.



